Managed Healthcare Executive February 24, 2024
Peter Wehrwein, Managing Editor

At the moment, Simlandi (adalimumab-ryvk) has the high-concentration, citrate-free, interchangeable Humira (adalimumab) market to itself.

The FDA has approved Simlandi (adalimumab-ryvk), which joins Pfizer’s Abrilada (adalimumab-afzb) and Boehringer Ingelheim’s Cyltezo (adalimumab-adbm) as interchangeable with AbbVie’s Humira’s (adalimumab), the reference brand-name product that has set all kinds of sales records, for some uses.

Interchangeability means the biosimilar can be substituted for the reference product or another biosimilar at the pharmacy level, although state-level pharmacy regulations can complicate matters. Interchangeability is widely seen as important for gaining market share in the increasingly crowded market for Humira biosimilars and for pharmacy benefit managers (PBMs) steering prescriptions to their preferred products.

A total of nine Humira biosimilars are on the market in the U.S.,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
To Give Rare Disease Patients Hope, the FDA Must Re-Focus its Efforts
Opinion: Adding psychotherapy to drug therapy works, but the FDA may not be able to handle it
FDA clears heart rhythm AI that turns smartphones into medical devices
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Accelerated Approval Pathway for Cancer Drugs: Does It Work?

Share This Article